AIDS Alert Archives – March 1, 2003
March 1, 2003
View Issues
-
OraSure begins shipping rapid HIV test to hospitals
After years of anticipation, the first of a new generation of rapid HIV tests is being shipped to hospitals and laboratories across the country. At the same time, health officials tell AIDS Alert that the OraQuick Rapid HIV-1 Anti-body Test soon could receive an Food and Drug Administration (FDA) waiver that would allow the test to be used in outreach settings as well. -
CLIA waiver crucial to rapid test adoption
An unpublished California study has found that more than half of new HIV infections came from sites that would not be able to use the OraQuick HIV rapid test as it is currently labeled. -
HIV prevention summit seeks new strategies
Hoping to refocus and re-energize the nations HIV prevention strategies, the Centers for Disease Control and Prevention (CDC) in Atlanta recently invited more than 125 HIV prevention experts for a two-day brainstorming session. -
Five different audits look at CDC’s HIV programs
The U.S. Office of the Inspector General is conducting four audits of the Center for Disease Control and Prevention (CDC), one of which is about to be completed and another that is soon to start. -
Prevention strategies abound during CDC summit
After two days of putting their heads together, a diverse group of HIV-prevention experts came up with dozens of proposed strategies. Here are some suggestions offered from one of four topic areas covered at a recent two-day HIV Prevention Summit at the Centers for Disease Control and Prevention in Atlanta. -
New CDC condom fact sheet invites criticism
An ongoing debate over the facts about condoms still is not settled, even though the Centers for Disease Control and Prevention (CDC) has posted an updated version of its on-line condom fact sheet. -
Attitude is key part of treatment adherence
A small Chicago study suggests that attitudes about HIV and AIDS among HIV-infected people can be broken down into types that are predictive of how well the patients will adhere to their medication regimens. -
FDA Notifications: New labeling for N-9 products?
Based on the results of several clinical trials, the Food and Drug Administration (FDA) has proposed new labeling for over-the-counter vaginal contraceptive drug products that contain nonoxynol 9 (N-9).